



The World Anti-Doping Code

THE 2013 PROHIBITED LIST INTERNATIONAL STANDARD

The official text of the *Prohibited List* shall be maintained by WADA and shall be published in English and French. In the event of any conflict between the English and French versions, the English version shall prevail.

This List shall come into effect on 1 January 2013



世界運動禁藥管制規範

2013 年運動禁藥禁用清單



運動禁藥禁用清單官方版本本由世界運動禁藥管制組織堅守，並以英文及法文出版。如英、法文版本有所抵觸，以英文版為主。（如中文譯本發生疑義，應以英文版本為主。）

本清單自 2013 年 1 月 1 日起生效

中華奧林匹克委員會運動禁藥管制組 翻譯

THE 2013 PROHIBITED LIST WORLD ANTI-DOPING CODE

Valid 1 January 2013

In accordance with Article 4.2.2 of the World Anti-Doping Code, all *Prohibited Substances* shall be considered as "Specified Substances" except Substances in classes S1, S2, S4.4, S4.5, S6.a, and *Prohibited Methods* M1, M2 and M3.

SUBSTANCES AND METHODS PROHIBITED AT ALL TIMES (IN- AND OUT-OF-COMPETITION)

PROHIBITED SUBSTANCES

S0. NON-APPROVED SUBSTANCES

Any pharmacological substance which is not addressed by any of the subsequent sections of the List and with no current approval by any governmental regulatory health authority for human therapeutic use (e.g. drugs under pre-clinical or clinical development or discontinued, designer drugs, substances approved only for veterinary use) is prohibited at all times.

S1. ANABOLIC AGENTS

Anabolic agents are prohibited.

1. Anabolic Androgenic Steroids (AAS)

a. Exogenous* AAS, including:

1-androstenediol (5 α -androst-1-ene-3 β ,17 β -diol); **1-androstenedione** (5 α -androst-1-ene-3,17-dione); **bolandiol** (estr-4-ene-3 β ,17 β -diol); **bolasterone**; **boldenone**; **boldione** (androsta-1,4-diene-3,17-dione); **calusterone**; **clostebol**; **danazol** ([1,2]oxazolo[4',5':2,3]pregna-4-en-20-yn-17 α -ol);

世界運動禁藥管制規範 2013 年禁用清單

2013 年 1 月 1 日生效施行

依世界運動禁藥管制規範第 4.2.2 條規定，除禁用物質 S1、S2、S4.4、S4.5、S6.a 及禁用方法 M1、M2、M3 外，所有禁用物質應視為「特定物質」。

隨時禁用的物質及方法 (賽內及賽外)

禁用物質

S0. 未經核可物質

任何未列入禁用清單且未經政府衛生主管機關核准用於人體治療（例如藥物仍在臨床前實驗階段或醫學臨床研究階段或取消許可、設計師藥物、核准只得用於動物之物質）之藥用物質。

S1. 同化性藥物

禁止使用同化性藥物

1. 同化性代謝雄性荷爾蒙(AAS)

a. 外生性*同化性代謝雄性荷爾蒙(AAS)包含下列藥物：

1-androstenediol (5 α -androst-1-ene-3 β ,17 β -diol); **1-androstenedione** (5 α -androst-1-ene-3,17-dione); **bolandiol** (estr-4-ene-3 β ,17 β -diol); **bolasterone**; **boldenone**; **boldione** (androsta-1,4-diene-3,17-dione); **calusterone**; **clostebol**; **danazol** ([1,2]oxazolo[4',5':2,3]pregna-4-en-20-yn-17 α -ol);

dehydrochlormethyltestosterone (4-chloro-17 β -hydroxy-17 α -methylandrosta-1,4-dien-3-one); **desoxymethyltestosterone** (17 α -methyl-5 α -androst-2-en-17 β -ol); **drostanolone**; **ethylestrenol** (19-norpregna-4-en-17 α -ol); **fluoxymesterone**; **formebolone**; **furazabol** (17 α -methyl[1,2,5]oxadiazolo[3',4':2,3]-5 α -androstan-17 β -ol); **gestrinone**; **4-hydroxytestosterone** (4,17 β -dihydroxyandrost-4-en-3-one); **mestanolone**; **mesterolone**; **metenolone**; **methandienone** (17 β -hydroxy-17 α -methylandrosta-1,4-dien-3-one); **methandriol**; **methasterone** (17 β -hydroxy-2 α ,17 α -dimethyl-5 α -androstan-3-one); **methyldienolone** (17 β -hydroxy-17 α -methylestra-4,9-dien-3-one); **methyl-1-testosterone** (17 β -hydroxy-17 α -methyl-5 α -androst-1-en-3-one); **methylnortestosterone** (17 β -hydroxy-17 α -methylestr-4-en-3-one); **methyltestosterone**; **metribolone** (methyltrienolone, 17 β -hydroxy-17 α -methylestra-4,9,11-trien-3-one); **mibolerone**; **nandrolone**; **19-norandrostenedione** (estr-4-ene-3,17-dione); **norboletone**; **norclostebol**; **norethandrolone**; **oxabolone**; **oxandrolone**; **oxymesterone**; **oxymetholone**; **prostanazol** (17 β -[(tetrahydropyran-2-yl)oxy]-1'H-pyrazolo[3,4:2,3]-5 α -androstande); **quinbolone**; **stanozolol**; **stenbolone**; **1-testosterone** (17 β -hydroxy-5 α -androst-1-en-3-one); **tetrahydrogestrinone** (17-hydroxy-18 α -homo-19-nor-17 α -pregna-4,9,11-trien-3-one); **trenbolone** (17 β -hydroxyestr-4,9,11-trien-3-one); and other substances with a similar chemical structure or similar biological effect(s).

b. Endogenous** AAS when administered exogenously:

androstenediol (androst-5-ene-3 β ,17 β -diol); **androstenedione** (androst-4-ene-3,17-dione); **dihydrotestosterone** (17 β -hydroxy-5 α -androstan-3-one); **prasterone** (dehydroepiandrosterone, DHEA, 3 β -hydroxyandrost-5-en-17-one); **testosterone**;

and their metabolites and isomers, including but not limited to:

5 α -androstane-3 α ,17 α -diol; **5 α -androstane-3 α ,17 β -diol**; **5 α -androstane-3 β ,17 α -diol**; **5 α -androstane-3 β ,17 β -diol**; **androst-4-ene-3 α ,17 α -diol**; **androst-4-ene-3 α ,17 β -diol**; **androst-4-ene-3 β ,17 α -diol**; **androst-5-ene-3 α ,17 α -diol**; **androst-5-ene-3 α ,17 β -diol**; **androst-5-ene-3 β ,17 α -diol**; **4-androstenediol** (androst-4-ene-3 β ,17 β -diol); **5-androstenedione** (androst-5-ene-3,17-dione); **epi-dihydrotestosterone**; **epitestosterone**; **etiocholanolone**; **3 α -hydroxy-5 α -androstan-17-one**; **3 β -hydroxy-5 α -androstan-17-one**; **7 α -hydroxy-DHEA** ; **7 β -hydroxy-DHEA** ; **7-keto-DHEA**; **19-norandrosterone**; **19-noretiocholanolone**.

2. Other Anabolic Agents, including but not limited to:

Clenbuterol, selective androgen receptor modulators (SARMs), tibolone, zeranol, zilpaterol.

dehydrochlormethyltestosterone (4-chloro-17 β -hydroxy-17 α -methylandrosta-1,4-dien-3-one); **desoxymethyltestosterone** (17 α -methyl-5 α -androst-2-en-17 β -ol); **drostanolone**; **ethylestrenol** (19-norpregna-4-en-17 α -ol); **fluoxymesterone**; **formebolone**; **furazabol** (17 α -methyl[1,2,5]oxadiazolo[3',4':2,3]-5 α -androstan-17 β -ol); **gestrinone**; **4-hydroxytestosterone** (4,17 β -dihydroxyandrost-4-en-3-one); **mestanolone**; **mesterolone**; **metenolone**; **methandienone** (17 β -hydroxy-17 α -methylandrosta-1,4-dien-3-one); **methandriol**; **methasterone** (17 β -hydroxy-2 α ,17 α -dimethyl-5 α -androstan-3-one); **methyldienolone** (17 β -hydroxy-17 α -methylestra-4,9-dien-3-one); **methyl-1-testosterone** (17 β -hydroxy-17 α -methyl-5 α -androst-1-en-3-one); **methylnortestosterone** (17 β -hydroxy-17 α -methylestr-4-en-3-one); **methyltestosterone**; **metribolone** (methyltrienolone, 17 β -hydroxy-17 α -methylestra-4,9,11-trien-3-one); **mibolerone**; **nandrolone**; **19-norandrostenedione** (estr-4-ene-3,17-dione); **norboletone**; **norclostebol**; **norethandrolone**; **oxabolone**; **oxandrolone**; **oxymesterone**; **oxymetholone**; **prostanazol** (17 β -[(tetrahydropyran-2-yl)oxy]-1'H-pyrazolo[3,4:2,3]-5 α -androstan-3-one); **quinbolone**; **stanozolol**; **stenbolone**; **1-testosterone** (17 β -hydroxy-5 α -androst-1-en-3-one); **tetrahydrogestrinone** (17-hydroxy-18 α -homo-19-nor-17 α -pregna-4,9,11-trien-3-one); **trenbolone** (17 β -hydroxyestr-4,9,11-trien-3-one); 及其他具有類似化學結構或相似生物作用的物質。

b. 由外部施用內生性**合成代謝雄性荷爾蒙：

androstenediol (androst-5-ene-3 β ,17 β -diol); **androstenedione** (androst-4-ene-3,17-dione); **dihydrotestosterone** (17 β -hydroxy-5 α -androstan-3-one); **prasterone** (dehydroepiandrosterone, DHEA); **testosterone** , 及其代謝物及同分異構物，包括但不僅限於下列：

5 α -androstan-3 α ,17 α -diol; **5 α -androstan-3 α ,17 β -diol**; **5 α -androstan-3 β ,17 α -diol**; **5 α -androstan-3 β ,17 β -diol**; **androst-4-ene-3 α ,17 α -diol**; **androst-4-ene-3 α ,17 β -diol**; **androst-4-ene-3 β ,17 α -diol**; **androst-5-ene-3 α ,17 α -diol**; **androst-5-ene-3 α ,17 β -diol**; **androst-5-ene-3 β ,17 α -diol**; **4-androstenediol** (androst-4-ene-3 β ,17 β -diol); **5-androstenedione** (androst-5-ene-3,17-dione); **epi-dihydrotestosterone**; **epitestosterone**; **etiocholanolone**; **3 α -hydroxy-5 α -androstan-17-one**; **3 β -hydroxy-5 α -androstan-17-one**; **7 α -hydroxy-DHEA** ; **7 β -hydroxy-DHEA** ; **7-keto-DHEA**; **19-norandrosterone**; **19-noretiocholanolone**.

2. 其他同化性物質包括但不僅限於下列：

Clenbuterol, 選擇性雄激素受體調節劑(**SARMs**), **tibolone**, **zeranol zilpaterol**

For purposes of this section:

* "exogenous" refers to a substance which is not ordinarily capable of being produced by the body naturally.

** "endogenous" refers to a substance which is capable of being produced by the body naturally.

S2. PEPTIDE HORMONES, GROWTH FACTORS AND RELATED SUBSTANCES

The following substances and their releasing factors are prohibited:

- 1. Erythropoiesis-Stimulating Agents [e.g. erythropoietin (EPO), darbepoetin (dEPO), hypoxia-inducible factor (HIF) stabilizers, methoxy polyethylene glycol-epoetin beta (CERA), peginesatide (Hematide)];**
- 2. Chorionic Gonadotrophin (CG) and Luteinizing Hormone (LH) in males;**
- 3. Corticotrophins;**
- 4. Growth Hormone (GH), Insulin-like Growth Factor-1 (IGF-1), Fibroblast Growth Factors (FGFs), Hepatocyte Growth Factor (HGF), Mechano Growth Factors (MGFs), Platelet-Derived Growth Factor (PDGF), Vascular-Endothelial Growth Factor (VEGF) as well as any other growth factor affecting muscle, tendon or ligament protein synthesis/degradation, vascularisation, energy utilization, regenerative capacity or fibre type switching;**

and other substances with similar chemical structure or similar biological effect(s).

S3. BETA-2 AGONISTS

All beta-2 agonists, including all optical isomers (e.g. *d*- and *l*-) where relevant, are prohibited except inhaled salbutamol (maximum 1600 micrograms over 24 hours), inhaled formoterol (maximum delivered dose 54 micrograms over 24 hours) and salmeterol when taken by inhalation in accordance with the manufacturers' recommended therapeutic regimen.

The presence in urine of salbutamol in excess of 1000 ng/mL or formoterol in excess of 40 ng/mL is presumed not to be an intended therapeutic use of the substance and will be considered as an *Adverse Analytical Finding* unless the *Athlete* proves, through a controlled pharmacokinetic study, that the abnormal result was the consequence of the use of the therapeutic inhaled dose up to the maximum indicated above.

依據本節宗旨：

* 「外生性物質」係指非由人體自然產生者

** 「内生性物質」係指由人體自然產生者

S2. 胜肽荷爾蒙、生長因子及相關物質

以下之禁用物質及相關釋放因子均禁用：

1. 紅血球生成劑【例如：紅血球生成素(EPO)、長效紅血球生成素darbepoetin (dEPO), 缺氧誘發因子(HIF)穩定劑, 超長效紅血球生成素(CERA), 人工合成胜肽紅血球生成素peginesatide (Hematide)】
2. 人類絨毛膜性腺激素(CG) 及黃體化激素(LH), 男性禁用
3. 促腎上腺皮質素
4. 生長荷爾蒙(GH), 似胰島素生長因子(IGF-1)、纖維母細胞生長因子(FGFs)、肝細胞生長因子(HGF)、機械生長因子 (MGFs)、血小板衍生性生長因子(PDGF)、血管內皮生長因子(VEGF)暨任何影響肌肉、肌腱、韌帶蛋白、合成/分解、血管形成、能量利用、再生能力或纖維改變之生長因子

及其他具有類似化學結構或相似生物作用的物質。

S3. Beta -2作用劑 (致效劑)

所有的Beta-2作用劑, 包括所有相關光學異構物 (例如D-型及L-型), 均禁止使用, 惟依藥商建議療法使用吸入式salbutamol (24小時內最高用量限1600 micrograms內)、吸入式formoterol (24小時內最高使用劑量限54 micrograms內) 及salmeterol者不在此限。

尿液中salbutamol濃度超過1000 ng/mL時或formoterol濃度超過40 ng/mL時, 認定非屬治療用途, 而係認定為負面分析結果, 除非經由控制藥物動力學研究結果, 選子能證明是項檢測結果係因吸入前述最高使用劑量範圍內之治療劑所致。

S4. HORMONE AND METABOLIC MODULATORS

The following are prohibited:

1. **Aromatase inhibitors** including, but not limited to: **aminoglutethimide, anastrozole, androsta-1,4,6-triene-3,17-dione (androstatrienedione), 4-androstene-3,6,17 trione (6-oxo), exemestane, formestane, letrozole, testolactone.**
2. **Selective estrogen receptor modulators (SERMs)** including, but not limited to: **raloxifene, tamoxifen, toremifene.**
3. **Other anti-estrogenic substances** including, but not limited to: **clomiphene, cyclofenil, fulvestrant.**
4. **Agents modifying myostatin function(s)** including, but not limited, to: **myostatin inhibitors.**
5. **Metabolic modulators:**
 - a) **Insulins**
 - b) **Peroxisome Proliferator Activated Receptor δ (PPAR δ) agonists (e.g. GW 1516), PPAR δ -AMP-activated protein kinase (AMPK) axis agonists (e.g. AICAR)**

S5. DIURETICS AND OTHER MASKING AGENTS

Masking agents are prohibited. They include:

Diuretics, desmopressin, plasma expanders (e.g. glycerol; intravenous administration of albumin, dextran, hydroxyethyl starch and mannitol), probenecid; and other substances with similar biological effect(s).

Local administration of felypressin in dental anaesthesia is not prohibited.

Diuretics include:

Acetazolamide, amiloride, bumetanide, canrenone, chlorthalidone, etacrynic acid, furosemide, indapamide, metolazone, spironolactone, thiazides (e.g. bendroflumethiazide, chlorothiazide, hydrochlorothiazide), triamterene; and other substances with a similar chemical structure or similar biological effect(s) (except drospirenone, pamabrom and topical dorzolamide and brinzolamide, which are not prohibited).

The use *In-* and *Out-of-Competition*, as applicable, of any quantity of a substance subject to threshold limits (i.e. formoterol, salbutamol, cathine, ephedrine, methylephedrine and pseudoephedrine) in conjunction with a diuretic or other masking agent requires the deliverance of a specific Therapeutic Use Exemption for that substance in addition to the one granted for the diuretic or other masking agent.

S4. 荷爾蒙及代謝調節劑

下列為禁用物質：

1. 芳香環轉化酶抑制劑：**aminoglutethimide, anastrozole, androsta-1,4,6-triene-3, 17-dione (androstatrienedione), 4-androstene-3,6,17 trione(6-oxo), exemestane, formestane, letrozole, testolactone**或類似作用物質。
2. 選擇性雌激素受體調節劑(**Selective Estrogen Receptor Modulators-SERMs**)：**raloxifene, tamoxifen, toremifene**或類似作用物質。
3. 其他抗雌激素物質亦在禁止之列：**clomiphene, cyclofenil, fulvestrant**或其他類似作用物質。
4. 改變肌肉生長抑制素機能：肌肉生長抑制素抑制劑**myostatin inhibitors**或其他類似作用物質。
5. 代謝調節劑：
 - a) 胰島素
 - b) 過氧化體增生劑活化受體**delta(PPAR δ)**致效劑(例如：**GW 1516**)，**PPAR δ -腺苷單磷酸活化蛋白激酶(AMPK)**活化劑(例如：**AICAR**)。

S5. 利尿劑及其他干擾劑

干擾劑為禁用物質，其包括：

利尿劑、**desmopressin**、血漿擴張劑(**plasma expanders**)〔如：甘油、靜脈注射**albumin, dextran, hydroxyethyl starch**和甘露醇(**mannitol**)〕、**probenecid**及其他具有相關生物作用之物質。牙科麻醉局部施用苯賴加壓素則不在此限。

利尿劑包括：

Acetazolamide, amiloride, bumetanide, canrenone, chlorthalidone, etacrynic acid, furosemide, indapamide, metolazone, spironolactone, thiazides(如**bendroflumethiazide, chlorothiazide, hydrochlorothiazide**)、**triamterene**及其他具有類似化學結構或相似生物作用之物質(如**drospirinone**、**pambrom**和局部的**dorzolamine**和**brinzolamide**不在禁用之列)。

賽內外使用任何閾值限量內的禁用物質，與利尿劑或其他干擾劑併用時(例如：**formoterol**、**salbutamol**、**cathine**、**ephedrine**、**methylephedrine**及**pseudoephedrine**)，除申請治療用途豁免核可使用利尿劑或其他干擾劑外，不論禁用物質用量多少都需另外申請該物質之特定治療用途豁免。

PROHIBITED METHODS

M1. MANIPULATION OF BLOOD AND BLOOD COMPONENTS

The following are prohibited:

1. The administration or reintroduction of any quantity of autologous, homologous or heterologous blood or red blood cell products of any origin into the circulatory system.
2. Artificially enhancing the uptake, transport or delivery of oxygen, including, but not limited to, perfluorochemicals, efaproxiral (RSR13) and modified haemoglobin products (e.g. haemoglobin-based blood substitutes, microencapsulated haemoglobin products), excluding supplemental oxygen.
3. Any form of intravascular manipulation of the blood or blood components by physical or chemical means.

M2. CHEMICAL AND PHYSICAL MANIPULATION

The following are prohibited:

1. *Tampering*, or attempting to tamper, in order to alter the integrity and validity of *Samples* collected during *Doping Control*. These include but are not limited to urine substitution and/or adulteration (e.g. proteases).
2. Intravenous infusions and/or injections of more than 50 mL per 6 hour period except for those legitimately received in the course of hospital admissions or clinical investigations.

M3. GENE DOPING

The following, with the potential to enhance sport performance, are prohibited:

1. The transfer of polymers of nucleic acids or nucleic acid analogues;
2. The use of normal or genetically modified cells.

禁 用 方 法

M1. 操控血液及血液成分

禁用下列方法：

1. 將自體、同源或異體的血液，或任何來源紅血球製品，不論數量多寡，施打或再引入循環系統。
2. 以人為方式增加氧氣吸收、運輸或傳送氧氣，包括且不僅限於全氟化合物、**efaproxiral (RSR13)**以及改造之血紅素產品（例如含血紅素之代用血液、微膠囊血紅素製劑），不包括補充氧氣。
3. 在血管內以任何物理或化學的方法操控血液或血液成分。

M2. 化學及物理操作

禁用下列方法：

1. 竄改或企圖竄改來改變運動禁藥管制作業中採樣檢體之完整性與有效性：人造假尿或變更尿液質性（例如：摻入蛋白酵素）或其他方法。
2. 靜脈注射及/或 6 小時內注射量超過 50mL，但在緊急醫療情況下並取得合法有效許可者不在此列。

M3. 基因禁藥

下列有提昇運動選手潛在成績者應予以禁止：

1. 轉殖核酸聚合物或核酸類似物。
2. 使用正常或基因改造細胞。

SUBSTANCES AND METHODS PROHIBITED IN-COMPETITION

**In addition to the categories S0 to S5 and M1 to M3 defined above,
the following categories are prohibited *In-Competition*:**

PROHIBITED SUBSTANCES

S6. STIMULANTS

All stimulants, including all optical isomers (e.g. *d*- and *l*-) where relevant, are prohibited, except imidazole derivatives for topical use and those stimulants included in the 2013 Monitoring Program*.

Stimulants include:

a: Non-Specified Stimulants:

**Adrafinil; amfepramone; amiphenazole; amphetamine; amphetaminil;
benfluorex; benzphetamine; benzylpiperazine; bromantan; clobenzorex;
cocaine; cropropamide; crotetamide; dimethylamphetamine;
etilamphetamine; famprofazone; fencamine; fenetylline; fenfluramine;
fenproporex; furfenorex; mefenorex; mephentermine; mesocarb;
methamphetamine(*d*-); p-methylamphetamine;
methylenedioxyamphetamine; methylenedioxymethamphetamine;
modafinil; norfenfluramine; phendimetrazine; phenmetrazine;
phentermine; 4-phenylpiracetam (carphedon); prenylamine; prolintane.**
A stimulant not expressly listed in this section is a Specified Substance.

b: Specified Stimulants (examples):

Adrenaline; cathine***; ephedrine****; etamivan; etilefrine; fenbutrazate;
fencamfamin; heptaminol; isometheptene; levmetamfetamine;
meclofenoxate; methylephedrine****; methylhexaneamine
(dimethylpentylamine); methylphenidate; nikethamide; norfenefrine;
octopamine; oxilofrine (methylsynephrine); parahydroxyamphetamine;
pemoline; pentetrazol; phenpromethamine; propylhexedrine;
pseudoephedrine****; selegiline; sibutramine; strychnine;
tuaminoheptane;** and other substances with a similar chemical structure or
similar biological effect(s).

賽 內 禁 用 物 質 及 方 法

除前面規定的 **S0** 至 **S5** 及 **M1** 至 **M3** 禁用物質及方法外，
下列規定物質賽內禁止使用。

禁 用 物 質

S6. 興奮劑

所有興奮劑，包括所有相關光學異構體（例如 *D-型* 及 *L-型*），均禁止使用，惟供局部使用imidazole衍生物，以及2013年監控計畫* 所列物質不在此限。

興奮劑包括：

a：非特定性興奮劑

**Adrafinil; amfepramone; amiphenazole; amphetamine; amphetaminil;
benfluorex; benzphetamine; benzylpiperazine; bromantan; clobenzorex;
cocaine; cropropamide; crotetamide; dimethylamphetamine;
etilamphetamine; famprofazone; fencamine; fenetylline; fenfluramine;
fenproporex; furfenorex; mefenorex; mephentermine; mesocarb;
methamphetamine(*d-*); *p*-methylamphetamine;
methylenedioxyamphetamine; methylenedioxymethamphetamine;
modafinil; norfenfluramine; phendimetrazine; phenmetrazine; phentermine;
4-phenylpiracetam (carphedon); prenylamine; prolintane.**

不在此列之興奮劑視為特定物質。

b：特定興奮劑（列舉）：

Adrenaline^{}; cathine^{***}; ephedrine^{****}; etamivan; etilefrine; fenbutrazate;
fencamfamin; heptaminol; isometheptene; levmetamfetamine;
meclofenoxate; methylephedrine^{****}; methylhexaneamine
(dimethylpentylamine); methylphenidate; nikethamide; norfenefrine;
octopamine; oxilofrine (methylsynephrine); parahydroxyamphetamine;
pemoline; pentetrazol; phenpromethamine; propylhexedrine;
pseudoephedrine^{*****}; selegiline; sibutramine; strychnine; tuaminoheptane;**
以及其他有相似化學結構及生物作用之物質。

* The following substances included in the 2013 Monitoring Program (bupropion, caffeine, nicotine, phenylephrine, phenylpropanolamine, pipradol, synephrine) are not considered as *Prohibited Substances*.

** Local administration (e.g. nasal, ophthalmologic) of **Adrenaline** or co-administration with local anaesthetic agents is not prohibited.

*** **Cathine** is prohibited when its concentration in urine is greater than 5 micrograms per milliliter.

**** Each of **ephedrine** and **methylephedrine** is prohibited when its concentration in urine is greater than 10 micrograms per milliliter.

***** **Pseudoephedrine** is prohibited when its concentration in urine is greater than 150 micrograms per milliliter.

S7. NARCOTICS

The following are prohibited:

Buprenorphine, dextromoramide, diamorphine (heroin), fentanyl and its derivatives, hydromorphone, methadone, morphine, oxycodone, oxymorphone, pentazocine, pethidine.

S8. CANNABINOIDS

Natural (e.g. cannabis, hashish, marijuana) or synthetic delta 9-tetrahydrocannabinol (THC) and cannabimimetics (e.g. "Spice", JWH018, JWH073, HU-210) are prohibited.

S9. GLUCOCORTICOSTEROIDS

All glucocorticosteroids are prohibited when administered by oral, intravenous, intramuscular or rectal routes.

- *列入 2013 年監控計畫之物質 (bupropion, caffeine, nicotine, phenylephrine, phenylpropanolamine, pipradol, synephrine) 不視為禁用物質。
- **局部施用腎上腺素 (例：鼻用及眼用) 或腎上腺素與局部麻醉劑併用時不在禁止之列。
- *****Cathine** 如於尿液中濃度高於 5 microgram/ml 視為禁用物質。
- ****如尿液中 **ephedrine** 及 **methylephedrine** 濃度高於 10 microgram/ml 則視為禁用物質。
- *****如尿液中的 **pseudoephedrine** 濃度高於 150 micrograms/ml 則視為禁用物質。

S7. 麻醉性止痛劑

下列為禁用之麻醉藥：

Buprenorphine, dextromoramide, diamorphine (heroin), fentanyl 及其衍生物, hydromorphone, methadone, morphine, oxycodone, oxymorphone, pentazocine, pethidine

S8. 大麻鹼素類

天然 (例如：大麻、印度大麻、大麻葉) 或合成四氫大麻醇 (THC) 暨 cannabimimetics (例如：「合成大麻」、JWH018、JWH073、HU-210) 均禁用。

S9. 腎上腺皮質素

禁止以口服、經直腸、靜脈注射或肌肉注射方式使用腎上腺皮質素。

SUBSTANCES PROHIBITED IN PARTICULAR SPORTS

P1. ALCOHOL

Alcohol (ethanol) is prohibited *In-Competition* only, in the following sports. Detection will be conducted by analysis of breath and/or blood. The doping violation threshold (haematological values) is 0.10 g/L.

- Aeronautic (FAI)
- Archery (FITA)
- Automobile (FIA)
- Karate (WKF)
- Motorcycling (FIM)
- Powerboating (UIM)

P2. BETA-BLOCKERS

Unless otherwise specified, beta-blockers are prohibited *In-Competition* only, in the following sports.

- Archery (FITA) (also prohibited *Out-of-Competition*)
- Automobile (FIA)
- Billiards (all disciplines) (WCBS)
- Darts (WDF)
- Golf (IGF)
- Shooting (ISSF, IPC) (also prohibited *Out-of-Competition*)
- Skiing/Snowboarding (FIS) in ski jumping, freestyle aerials/halfpipe and snowboard halfpipe/big air

Beta-blockers include, but are not limited to, the following:

Acebutolol, alprenolol, atenolol, betaxolol, bisoprolol, bunolol, carteolol, carvedilol, celiprolol, esmolol, labetalol, levobunolol, metipranolol, metoprolol, nadolol, oxprenolol, pindolol, propranolol, sotalol, timolol.

特 定 運 動 種 類 的 禁 用 物 質

P1. 酒精

酒精（乙醇）僅在下列運動之賽內禁用。檢驗方式為吹氣檢測及/或驗血。各單項運動總會所訂違反運動禁藥管制規定的標準值（血值）為0.10g/L：

- 飛行運動(FAI)
- 射箭(FITA)
- 汽車賽車(FIA)
- 空手道(WKF)
- 機車賽車(FIM)
- 賽艇(UIM)

P2. β 阻斷劑

除另有規定外，下列運動僅在賽內禁用BETA阻斷劑：

- 射箭(FITA)〔賽外亦禁用〕
- 汽車賽車(FIA)
- 撞球〔包括所有項目〕(WCBS)
- 飛鏢(WDF)
- 高爾夫(IGF)
- 射擊(ISSF、IPC)〔賽外亦禁用〕
- 滑雪/滑板(FIS)—飛躍滑雪、自由式空中/半管滑雪，以及半管/空中滑板

乙型交感神經阻斷劑包括但不僅止於下列物質：

Acebutolol, alprenolol, atenolol, betaxolol, bisoprolol, bunolol, carteolol, carvedilol, celiprolol, esmolol, labetalol, levobunolol, metipranolol, metoprolol, nadolol, oxprenolol, pindolol, propranolol, sotalol, timolol.

THE 2013 MONITORING PROGRAM*

The following substances are placed on the 2013 Monitoring Program:

- 1. Stimulants:** ***In-Competition only:*** *Bupropion, caffeine, nicotine, phenylephrine, phenylpropanolamine, pipradrol, pseudoephedrine (< 150 micrograms per milliliter), synephrine.*

- 2. Narcotics:** ***In-Competition only:*** *Hydrocodone, morphine/codeine ratio; tapentadol; tramadol.*

- 3. Glucocorticosteroids: *Out-of-Competition only***

* The *World Anti-Doping Code* (Article 4.5) states: "WADA, in consultation with Signatories and governments, shall establish a monitoring program regarding substances which are not on the Prohibited List, but which WADA wishes to monitor in order to detect patterns of misuse in sport."

2013年監控計畫*

下列物質列入2013年監控計畫：

1. 興奮劑：僅限賽內：*Bupropion, caffeine, nicotine, phenylephrine, phenylpropanolamine, pipradrol, pseudoephedrine (濃度低於150 microgram/ml), synephrine.*
2. 麻醉劑：僅限賽內：*Hydrocodone, morphine/codeine 比值; tapentadol; tramadol.*
3. 腎上腺皮質素：僅限賽外

* 依世界運動禁藥管制規範第4.5條揭示：「世界運動禁藥管制組織應與簽署認可運動禁藥管制作業單位及政府協商監控未在運動禁藥清單之列物質以瞭解運動選手濫用藥物之情形。」